6 active not recruiting, 6 completed. 12 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 6, Completed 6 |
| Phase 1 | 5 | Active not recruiting 3, Completed 2 |
Follow berzosertib: new trials by email Literature Review of berzosertib trials Research Report on berzosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Berzosertib, Sacituzumab Govitecan - HRD Cancer, SCLC | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2021-09-20 | 2026-07-21 |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers Lurbinectedin, Berzosertib - SCLC, Small Cell Cancer | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 37 | 2021-06-01 | 2026-03-17 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2021-04-14 | 2026-11-13 |
| Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) Berzosertib, Topotecan - Small-cell Lung Cancer | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 76 | 2021-03-29 | 2024-09-26 |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2020-11-16 | 2026-10-20 |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Avelumab, Berzosertib - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 23 | 2020-03-17 | 2026-11-10 |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs Berzosertib, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 104 | 2019-12-30 | 2026-11-13 |
| M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Berzosertib, Carboplatin, Docetaxel - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 73 | 2019-05-29 | 2026-11-13 |
| M6620 (VX-970) in Selected Solid Tumors M6620 - Solid Tumor, Leiomyosarcoma | Phase 2 | Completed | Massachusetts General Hospital | 30 | 2019-01-08 | 2023-07-07 |
| Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer Berzosertib, Cisplatin, Gemcitabine Hydrochloride - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 87 | 2017-01-31 | 2025-03-03 |
| Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Berzosertib, Gemcitabine, Gemcitabine Hydrochloride - Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-08-25 | 2026-11-13 |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers Topotecan, VX-970 (M6620) - Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 62 | 2015-07-30 | 2025-04-13 |
Small Cell Lung Carcinoma (4) · Ovarian Neoplasms (2) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Fallopian Tube Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Leiomyosarcoma (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Osteosarcoma (1) · Prostatic Neoplasms (1) · Uterine Cervical Neoplasms (1)
National Cancer Institute (NCI) (9) · EMD Serono Research & Development Institute, Inc. (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1)
United States (12) · Belgium (1) · China (1) · France (1) · Italy (1) · Japan (1) · Spain (1)
Anish Thomas, M.D. (3) · Arun Rajan (1) · Atish D Choudhury (1) · Gregory M Cote, MD, PhD (1) · Jordan D Berlin (1) · Liza C Villaruz (1) · Panagiotis A Konstantinopoulos (1) · Sumanta K Pal (1) · Timothy A Yap (1)
PMID 42820295, PMID 29252124, PMID 31401903, PMID 32553118, PMID 34436521, PMID 37491889, PMID 37824137, PMID 38635934, PMID 41206673, PMID 41335461
UM1CA186690 (2), UM1CA186709 (2), N01CM00038 (1), UM1CA186689 (1), UM1CA186717 (1), ZIABC011078 (1)